Dr Hauschild speaks with ecancertv at WCCS 2016 with updates from recent trials in checkpoint inhibition therapy.
He discusses the Hedgehog inhibitor tested through the VISMO trial to treat basal cell carcinoma, and the BRIM trials of vemurafinib ± cobimetinib.
Dr Hauschild also considers the the results of Checkmate and Keynote trials of PD1/PDL1 biomarkers presented as ASCO 2016, which was reported by ecancer here, and the economic viability of these treatments across Europe.
ecancer's filming at WCCS 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.